BR112017011457A2 - métodos e composições relacionados a polipeptídeos funcionais incorporados em suportes de proteína heteróloga - Google Patents

métodos e composições relacionados a polipeptídeos funcionais incorporados em suportes de proteína heteróloga

Info

Publication number
BR112017011457A2
BR112017011457A2 BR112017011457A BR112017011457A BR112017011457A2 BR 112017011457 A2 BR112017011457 A2 BR 112017011457A2 BR 112017011457 A BR112017011457 A BR 112017011457A BR 112017011457 A BR112017011457 A BR 112017011457A BR 112017011457 A2 BR112017011457 A2 BR 112017011457A2
Authority
BR
Brazil
Prior art keywords
incorporated
methods
functional
support
heterologous protein
Prior art date
Application number
BR112017011457A
Other languages
English (en)
Inventor
A Lerner Richard
M Lindsay Ronald
Peng Yingjie
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of BR112017011457A2 publication Critical patent/BR112017011457A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin

Abstract

a presente invenção refere-se a métodos para a produção de derivados funcionais de polipeptídeos efetores (por exemplo, hormônios e ligantes de receptor) incorporados em um suporte de proteína diferente (por exemplo, suportes de anticorpo). os métodos envolvem modificar o polipeptídeo efetor com uma biblioteca combinatória de sequências ligantes terminais, inserir as sequências modificadas no suporte hospedeiro e, em seguida, realizar a separação de derivados funcionais a partir da biblioteca de sequências de polipeptídeos modificados incorporados no suporte hospedeiro. como exemplificações, a invenção também fornece derivados funcionais específicos de leptina, scfsh e screlaxina incorporados em um suporte de anticorpo, bem como aplicações terapêuticas de tais moléculas de fusão funcionais.
BR112017011457A 2014-12-01 2015-12-01 métodos e composições relacionados a polipeptídeos funcionais incorporados em suportes de proteína heteróloga BR112017011457A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462085807P 2014-12-01 2014-12-01
US201562222384P 2015-09-23 2015-09-23
PCT/US2015/063126 WO2016089829A1 (en) 2014-12-01 2015-12-01 Methods and compositions related to functional polypeptides embedded in heterologous protein scaffolds

Publications (1)

Publication Number Publication Date
BR112017011457A2 true BR112017011457A2 (pt) 2018-04-03

Family

ID=56092310

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017011457A BR112017011457A2 (pt) 2014-12-01 2015-12-01 métodos e composições relacionados a polipeptídeos funcionais incorporados em suportes de proteína heteróloga

Country Status (11)

Country Link
US (1) US10941188B2 (pt)
EP (1) EP3227477A4 (pt)
JP (1) JP2017536833A (pt)
CN (1) CN107208315A (pt)
AU (1) AU2015355191B2 (pt)
BR (1) BR112017011457A2 (pt)
CA (1) CA2969220A1 (pt)
EA (1) EA201790946A8 (pt)
IL (1) IL252410A0 (pt)
MX (1) MX2017007393A (pt)
WO (1) WO2016089829A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201711208D0 (en) 2017-07-12 2017-08-23 Iontas Ltd Ion channel inhibitors
KR20210027230A (ko) 2017-10-04 2021-03-10 옵코 파마슈티칼스, 엘엘씨 암의 개인 맞춤형 치료에 관한 물품 및 방법
TW202016125A (zh) * 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
US20230348586A1 (en) * 2020-09-21 2023-11-02 The Board Of Regents Of The University Of Texas System Therapeutic agents and uses thereof
CN114213523A (zh) * 2021-11-15 2022-03-22 广州源博医药科技有限公司 一种用于重组蛋白的高糖基化修饰序列及其重组猪促卵泡激素和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2102339A2 (en) * 2007-01-12 2009-09-23 Sea Lane Biotechnologies,llc. Combinatorial libraries of conformationally constrained polypeptide sequences
US20110243943A1 (en) * 2010-04-02 2011-10-06 Athena Discovery, Inc. Treatment using relaxin-fusion proteins with extended in vivo half-lives
AU2013208003B2 (en) * 2012-01-09 2017-12-14 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
EP3121194A1 (en) * 2012-03-14 2017-01-25 Innovative Targeting Solutions Inc. Generating targeted sequence diversity in fusion proteins
JP6590694B2 (ja) * 2012-08-31 2019-10-16 ザ スクリプス リサーチ インスティテュート 真核生物細胞の調節因子に関する方法及び組成物
CN105073781A (zh) * 2013-01-11 2015-11-18 加州生物医学研究所 牛融合抗体
US20150017162A1 (en) * 2013-03-15 2015-01-15 Omeros Corporation Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same

Also Published As

Publication number Publication date
CA2969220A1 (en) 2016-06-09
EP3227477A1 (en) 2017-10-11
WO2016089829A1 (en) 2016-06-09
EA201790946A8 (ru) 2018-10-31
US20180298051A1 (en) 2018-10-18
EA201790946A1 (ru) 2018-04-30
AU2015355191A1 (en) 2017-06-08
MX2017007393A (es) 2020-02-24
IL252410A0 (en) 2017-07-31
EP3227477A4 (en) 2018-05-09
US10941188B2 (en) 2021-03-09
CN107208315A (zh) 2017-09-26
AU2015355191B2 (en) 2020-04-30
JP2017536833A (ja) 2017-12-14

Similar Documents

Publication Publication Date Title
BR112017011457A2 (pt) métodos e composições relacionados a polipeptídeos funcionais incorporados em suportes de proteína heteróloga
BR112018011073A2 (pt) anticorpos antimiostatina, polipeptídeos contendo regiões fc variantes e métodos de utilização
BR112019007433A2 (pt) sistemas de replicon de vírus recombinante e usos dos mesmos
BR112019007288A2 (pt) proteína heterodimérica biespecífica, composições de ácido nucleico e de vetor de expressão, vetor de expressão, célula hospedeira, e, métodos para produzir proteína heterodimérica biespecífica e para tratar câncer em um paciente
BR112019007369A2 (pt) anticorpos anti-lag-3 e métodos de uso dos mesmos
BR112017025564A2 (pt) anticorpos anti-ctla-4 e métodos de uso dos mesmos
EA201991383A1 (ru) Антитела против ctla-4 и способы их применения
PE20210107A1 (es) Anticuerpos anti-cd3 y metodos de uso
PH12020550240A1 (en) D-domain containing polypeptides and uses thereof
BR112018010429A2 (pt) ácidos nucleicos que se direcionam a ácidos nucleicos engenheirados
MX2022003698A (es) Composiciones de nanoparticulas y metodos para inmunoterapia.
BR112016014810A2 (pt) Antagonistas de fcrn e métodos de uso
BR112017006598A2 (pt) anticorpo de repetições antidipeptídeo derivado de ser humano (dprs)
BR112016016658A2 (pt) proteína de fusão de um anticorpo, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica, métodos para produzir uma proteína de fusão e de tratamento de uma doença em um indivíduo e uso da proteína de fusão
BR112016010706A2 (pt) anticorpo biespecífico, composição farmacêutica, uso do anticorpo biespecífico, sequência de ácido nucleico, vetor de expressão, célula hospedeira e método de produção de um anticorpo
MY193481A (en) Method and compositions comprising purified recombinant polypeptides
BR112016014913A8 (pt) anticorpo, ou um fragmento de ligação ao antígeno do mesmo, conjugado, ácido nucléico, vetor, célula hospedeira, composição farmacêutica, método de preparo de uma cadeia leve de um anticorpo ou fragmento de ligação ao antígeno e método de preparo de um conjugado
WO2018081592A3 (en) Compositions and methods for the production of compounds
BR112016027222A2 (pt) anticorpos isolados, ácido nucleico isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, métodos de tratamento de um indivíduo com um câncer, de inibição da proliferação de uma célula, de detecção de gpc3 humano e de detecção de um câncer
BR112017003472A2 (pt) anticorpos, fragmento fab de anticorpo e método para o tratamento de uma doença inflamatória
BR112016020822A2 (pt) Métodos e composições para secreção de polipeptídeos heterólogos
BR112019004459A2 (pt) métodos para purificar anticorpos
CY1120997T1 (el) Πρωτεϊνες συντηξης uti
MX2015017959A (es) Composiciones y metodos para inmunoterapia.
AR080680A1 (es) Proteinas de union a basigina

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]